Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: A pooled analysis of Phase 3 clinical trials

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 1, 2017, Pages 268-272

  Popejoy, Myra W ^a   Paterson, David L ^b   Cloutier, Daniel ^a   Huntington, Jennifer A ^a   Miller, Benjamin ^a   Bliss, Caleb A ^a   Steenbergen, Judith N ^a   Hershberger, Ellie ^a   Umeh, Obiamiwe ^a   Kaye, Keith S ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; THIENAMYCIN DERIVATIVE; URINARY TRACT ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; CLINICAL OUTCOME; DRUG EFFICACY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GENOTYPE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MIC50; MIC90; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY TRACT INFECTION; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENETICS; INTRAABDOMINAL INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA INFECTIONS; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS); TREATMENT OUTCOME; URINARY TRACT INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS, URINARY; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEPHALOSPORINS; DOUBLE-BLIND METHOD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENOTYPE; HUMANS; INTRAABDOMINAL INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LEVOFLOXACIN; MALE; METRONIDAZOLE; MIDDLE AGED; PENICILLANIC ACID; THIENAMYCINS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 85014538017     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw374     Document Type: Article

References (20)

1. Adler A, Katz DE, Marchaim D. The continuing plague of extendedspectrum b-lactamase-producing Enterobacteriaceae infections. Infect Dis Clin North Am 2016; 30: 347-75.
2. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
3. Schwaber MJ, Navon-Venezia S, Kaye KS et al. Clinical and economic impact of bacteremia with extended-spectrum-blactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257-62.
4. Collins VL, Marchaim D, Pogue JM et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-blactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012; 56: 2173-7.
5. Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extendedspectrum b-lactamases. Clin Infect Dis 2004; 39: 31-7.
6. Zerbaxa (Ceftolozane and Tazobactam) Prescribing Information. Whitehouse Station, NJ, USA: Merck & Co., Inc.; 2015.
7. Farrell DJ, Flamm RK, Sader HS et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57: 6305-10.
8. Sader HS, Farrell DJ, Flamm RK et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014; 69: 266-77.
9. Wagenlehner FM, Umeh O, Steenbergen J et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, doubleblind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385: 1949-56.
10. Solomkin J, Hershberger E, Miller B et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 2015; 60: 1462-71.
11. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
12. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 5.0, 2015. http://www.eucast.org.
13. Zerbaxa (Ceftolozane and Tazobactam) Summary of Product Characteristics. Hertfordshire, UK: Merck & Co., Inc.; 2016.
14. WHO. Antimicrobial Resistance: Global Report on Surveillance 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/.
15. Harris PN, Tambyah PA, Paterson DL. β-Lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal? Lancet Infect Dis 2015; 15: 475-85.
16. HobanDJ, Badal R, BouchillonSet al. In vitro susceptibility and distribution of β-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011. Diagn Microbiol Infect Dis 2014; 79: 367-72.
17. Doern GV, Brecher SM. The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests. J Clin Microbiol 2011; 49 Suppl 9: S11-4.
18. Tamma PD, Han JH, Harris AD et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 2015; 60: 1319-25.
19. Livermore DM. β-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998; 41 Suppl D: 25-41.
20. Melchers MJ, van Mil AC, Mouton JW. In vitro activity of ceftolozane alone and in combination with tazobactam against extendedspectrum-b-lactamase-harboring Enterobacteriaceae. Antimicrob Agents Chemother 2015; 59: 4521-5.